Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ALL patients' liver toxicities linked to antibiotics, other therapies

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Key clinical point: Liver toxicity with pegylated asparaginase (PEG-ASP) may be linked to concomitant chemotherapeutics or antibiotics in ALL.

Major finding: Idarubicin was associated with a higher risk of grade 3 or 4 hepatotoxicity, and vincristine was associated with a borderline risk.

Study details: Retrospective review of 51 PEG-ASP dosing events in 26 adult patients with ALL.

Disclosures: The study was internally funded. The authors reported having no relevant conflicts of interest.

Source: Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Read the article.

Citation:

Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

This Week's Must Reads

ALL patients' liver toxicities linked to antibiotics, other therapies, Minetto P et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PS934.

Thrombocytopenia in pregnancy raises risk of complications, Reese J et al. N Engl J Med. 2018;379:32-43.

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.

PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.

Hydroxyurea tolerated well in sickle cell patients, Dauvergne B et al. FSCDR 2018 (annual meeting of the Foundation for Sickle Cell Disease Research), presentation JSCDH-D-18-00052.